Therefore, XN suppresses angiogenesis by reducing VEGF secretion in leukemic cells, interfering with the cascades inducing NF-κB activation, and inhibiting Akt phosphorylation via suppression of Akt/NF-κB signaling in U937 chronic myelogenous leukemia [113], similar to the observed inhibitory effects in HUVECs [114]. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.